The following video is part of our "Motley Fool Conversations" series in which technology editor/analyst Andrew Tonner and health-care editor/analyst David Williamson discuss topics across the investing world.
In this video, Andrew and David sit down to talk about the continuing acquisitions Big Pharma is making to acquire next gen hepatitis-C treatments. They go over the most recent deal, Bristol-Myers Squibb's $2.5 billion purchase of Inhibitex, compare it to Gilead's purchase of Pharmasset, and discuss which company would be next at the altar if buyout mania keeps going.
Biotech investors are always looking for the next runaway success. Motley Fool co-founder David Gardner has recently identified a small-cap health-care company that he believes is poised for monster returns. To find out which stock is about to reap huge profits from fundamentally changing its industry download our exclusive special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited time offer and your opportunity to discover this game changing company before the market does by. Click here to access your report -- it's totally free.
